Skip to main content
Dataset
Data from: A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes
Pediatric Research Data
  • Benjamin U. Nwosu, University of Massachusetts Medical School
  • Louise Maranda, University of Massachusetts Medical School
  • Karen Cullen, University of Massachusetts Medical School
  • Lisa Greenman, University of Massachusetts Medical School
  • Jody Fleshman, University of Massachusetts Medical School
  • Nancy McShea, University of Massachusetts Medical School
  • Bruce A. Barton, University of Massachusetts Medical School
  • Mary M. Lee, University of Massachusetts Medical School
UMMS Affiliation
Department of Pediatrics, Division of Pediatric Endocrinology; Department of Quantitative Health Sciences
Document Type
Data
File Format & Size
.xlsx (33 KB)
Identifier
Clinical trial identification number: ClinicalTrial.gov NCT01334125
Publication Date
7-1-2015
Funders
This study was supported by an investigator-initiated research grant to Benjamin U. Nwosu from Novo Nordisk, Inc. This study was also supported by the University of Massachusetts (UMass) Center for Clinical and Translational Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Grant Number
H-13938, UL1 TR001453, UL1 TR001453
Keywords
  • UMCCTS funding,
  • type 1 diabetes mellitus,
  • biguanides,
  • metformin,
  • insulin resistance
Description

Manuscript abstract:

CONTEXT: Insulin resistance has been proposed as one of the causes of poor glycemic control in overweight/obese youth with type 1 diabetes (T1D). However, the role of adjunctive metformin, an insulin sensitizer, on glycemic control in these patients is unclear.

OBJECTIVE: To compare the effect of metformin vs. placebo on hemoglobin A1c (HbA1c), total daily dose (TDD) of insulin, and other parameters in overweight/obese youth with T1D.

HYPOTHESIS: Adjunctive metformin therapy will improve glycemic control in overweight/obese youth with T1D.

DESIGN, SETTING, AND PARTICIPANTS: A 9-mo randomized, double-blind, placebo controlled trial of metformin and placebo in 28 subjects (13m/15f) of ages 10-20years (y), with HbA1c >8% (64 mmol/mol), BMI >85%, and T1D > 12 months was conducted at a university outpatient facility. The metformin group consisted of 15 subjects (8 m/ 7f), of age 15.0 ± 2.5 y; while the control group was made up of 13 subjects (5m/ 8f), of age 14.5 ± 3.1y. All participants employed a self-directed treat-to-target insulin regimen based on a titration algorithm of (-2)-0-(+2) units to adjust their long-acting insulin dose every 3rd day from -3 mo through +9 mo to maintain fasting plasma glucose (FPG) between 90-120 mg/dL (5.0-6.7 mmol/L). Pubertal maturation was determined by Tanner stage.

RESULTS: Over the course of the 9 months of observation, the between-treatment differences in HbA1c of 0.4% (9.85% [8.82 to 10.88] for placebo versus 9.46% [8.47 to 10.46] for metformin) was not significant (p = 0.903). There were non-significant reduction in fasting plasma glucose (189.4 mg/dL [133.2 to 245.6] for placebo versus 170.5 mg/dL [114.3 to 226.7] for metformin), (p = 0.927); total daily dose (TDD) of short-acting insulin per kg body weight/day(p = 0.936); and the TDD of long-acting insulin per kg body weight per day (1.15 units/kg/day [0.89 to 1.41] for placebo versus 0.90 units/kg/day [0.64 to 1.16] for metformin) (p = 0.221). There was no difference in the occurrence of hypoglycemia between the groups.

CONCLUSIONS: This 9-month RCT of adjunctive metformin therapy in overweight and obese youth with T1D resulted in a 0.4% lower HbA1c value in the metformin group compared to the placebo group.

Data Collection Start Date
2011
Data Collection End Date
2014
Methodology

Methodology is documented in published manuscript.

Publisher
eScholarship@UMMS
Language
eng
Code Lists

The code list for this dataset is available under "Additional Files."

Creative Commons License
Creative Commons Attribution 4.0
Citation Information
Benjamin U. Nwosu, Louise Maranda, Karen Cullen, Lisa Greenman, et al.. "Data from: A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes" (2015)
Available at: http://works.bepress.com/benjamin_nwosu/37/